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INTRODUCTION 
 
The pharmaceutical manufacturing model has two 
main splits: a development organization responsible for 
new product development and getting FDA approval 
for drug products and a commercial organization re-
sponsible for marketing of those products. However, 
there occurs an additional group, called medical affairs 
(MA) which act as a bridge between development and 
commercialization [1]. 
Healthcare providers (HCPs) have the ability to provide 
appropriate therapies to sick owing to their medical 
knowledge. Now-a-days, due to multifaceted therapeu-
tic options there is a necessity of   continuous update 
and expansion of the knowledge base of the HCPs so 
that they can provide the best treatments possible. MA 
professionals within the pharmaceutical industry are 
capable to bridge this information gap because of their 
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scientific and medical expertise background. They can 
establish themselves with their “physician base” and 
can act as reliable source for scientifically sound medi-
cal communications. In the past 10 years there is an 
emerging role for the MA as a core competency within 
the pharmaceutical industry [2]. MA plays a multifunc-
tional role in the pharmaceutical industry like involve-
ment in strategic medical communications planning 
and implementation across the product lifecycle 
(lifecycle management post initial indication approval). 
As the role of MA has increased, there is a need and 
responsibility to update the medical fraternity for novel 
treatment approaches and advances from the clinical 
research stage for an indication. The activities like dis-
ease state awareness, publication planning, and prod-
uct launch communication collaterals, and post-launch 
phase IV planning frequently require specific medical 
expertise which can be provided by MA team. Initially 
the responsibility for strategic planning was exclusively 
assigned to commercial teams but today there is a task 
shift in the prelaunch phase to a function started by the 
MA team. The MA professionals provide their valuable 
inputs with strict adherence to accurate scientific inter-
pretation of data specific for product or disease state 
or both. MA teams may provide their contribution to 
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external thought leaders (key opinion leaders (KOL) and 
clinicians by providing an in-depth knowledge of spe-
cific disease states and the parallel role of pharmaceuti-
cals. In this way MA can aid HCPs remain updated and 
translate cutting-edge science to fulfil unmet clinical 
needs and eventually provide better patient care [2]. 
Definition of MA according to the Accreditation Coun-
cil for Medical Affairs (ACMA)  
“…provides medical support for development stage as 
well as commercialized products including post-
marketing studies (PMS), safety, and surveillance, and 
product support. The main responsibility for medical or 
drug based information, is to provide a comprehensive, 
product compliant, and disease state information to 
HCPs and consumers” [3]. 
Key Proficiencies of Medical Affairs: MA has developed 
into a discrete medical organization that is associated 
with development organizations but mainly works on 
post-approval activities by providing support through 
its scientific and clinical expertise. Some of the im-
portant functions of MA are illustrated in Figure 1 [1]. 
A Medical Affairs Portfolio [4] 
Medical field teams: including medical science liaisons 
(MSLs), responsible for relationship management and 
communication of product information with HCPs, reg-
ulators and institutional leaders. 
Post-launch clinical trials: involved in planning and 
conducting of phase IIIb/IV company-sponsored inter-
ventional and observational studies and support of 
investigator-initiated studies (IIS). 
Medical information: including the medical staff in 
centralized call centers to disseminate medical infor-
mation in response to drug-related queries. 
Medical communications: including the writing and 
support for peer-reviewed journal publications and 
other medical and scientific inputs. 
Medical education: Including the planning and funding 
support for continuing medical education (CMEs) for 
HCPs and the sales force training. 
Medical strategic activities: The development of the 
medical-brand strategy for each product by medical 
directors and to develop the product’s cross-functional 
life-cycle strategy in alliance with development, com-
mercial, regulatory and other departments. 
Health economics and outcomes-research (HEOR) 
activities: including research and communications re-
lated to product value like product value dossiers, pa-
tient-related outcomes, health technology assess-
ments. 
Recognizing the capabilities of MA and the correct time 
to constitute its respective functional teams is vital for 
preparing for and executing a successful drug product 
launch [1-5]. 
Medical communications/publications [1] 
It is a MA group primarily responsible for all clinical 
research publications such as abstracts, posters, and 
manuscripts. These types of medical communication 
input are important for product commercialization. 
Besides, medical communications is also involved in 
strategizing the plan that incorporates the timing of 
clinical trial data with the announcement of main data 
points at scientific meetings. This plan indicates the 
timing of abstract submissions and manuscript publica-
tions in the years leading up to and following a launch. 
The publication of interim data (like for either early 
stage or pivotal trials, which might occur months to 
years before drug approval (T – 24 to T – 12; or 24 to 
12 months before launch) is a part of this publication 
planning. The correct interpretation of clinical trial data 
and presenting it in clear and concise form for the or-
ganization as a whole is also one of the primary role of 
Figure 1. Medical Affairs Functions [1]  
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medical communications group. Besides, the publica-
tion of data post-approval of drug is more critical and 
medical communications propose publication plan to 
maximize the amount of exposure, and recognition for 
a new drug product [1]. 
Medical Science Liaisons (MSLs) [1] 
MSLs form field based teams of MA who nurture rela-
tionships with both external and internal stakeholders 
by their scientific and clinical expertise. For external 
stakeholders, an MSL team functions as the “medical” 
face of the company in a very distinctive way from 
sales force. Primarily, it is responsible for maintaining 
strong relationships with both community and academ-
ic physicians and acts an effective channel for a flow of 
information both to HCPs and into a company itself.  
For internal stakeholders, an MSL team can use its 
strong relationships with other major corporate de-
partments to help external stakeholders understand 
internal infrastructure of the company. 
An MSL team is ideally constituted sometime before 24 
to 12 months of product launch. This time period helps 
in gaining in-depth understanding of the disease state 
and therapeutic landscape, learning all drug-related 
aspects, and establishing relationships with key exter-
nal stakeholders (KOLs, important organizations, and 
payers). The success of the product depends on all 
these in place at the time of product launch. 
 
Medical information [1] 
A medical information group provides answers to all 
queries related to commercial drug products like safe-
ty, efficacy, posology, and administration. This group of 
MA generally is first recipients of the queries from pa-
tients, HCPs, and other interested parties during the 
product launch. They prepare commercial product 
launch materials and/or sales training. The group is 
typically framed before 24-12 months before product 
launch. 
 
Medical affairs Activities [4,5] 
MA is a single point of contact across departments 
within the organization and outside stakeholders also. 
As discussed above this organization is important for 
knowledge collection and dissemination (Figure 2). 
Data generation, maintenance and presentation are 
important for smooth functioning of MA 
Data generation and maintenance [5]: 
• Finding and outlining of scientific peers 
Figure 2. Types of activities by MA for external and internal stakeholders 
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• Deciding the best possible role is for each of the 
scientific peers 
• Knowledge of the patient flow 
• An effective risk management plan for character-
izing risks associated with the product 
•Clinical and observational studies, drug utilization 
studies, epidemiological data and HEOR. 
Data presentation [5]: Developing a market access plan 
based on clinical evidence of efficacy and safety of the 
product together with the epidemiological data to ex-
plore the unmet medical need. 
Essential Driving Forces for Medical Affairs [6] 
As the experts speak MA provide medical and scientific 
advice throughout the drug’s life cycle by developing 
and communicating data that address patients’ unmet 
need and progress in the treatment of the disease. 
they categorized driving forces for MA in nine broad 
heads: 
1. Joint Leadership: Partnerships with internal and 
external stakeholders.  
2. Customer/ patient Focus: Strategic develop of  so-
lutions for customer requirements 
3. Strategic Visualization: Application of medical 
knowledge to a “broad landscape” in strategic plan-
ning and decision making 
4. Dexterity: Decisive, flexible, dynamic approach and 
entrepreneurial attitude 
5. Business Insight: Instituting a holistic understand-
ing to bridge a gap between development and com-
mercial phases of drug.  
6. Innovation: A futuristic projection of environmental 
needs and independent thinking 
7. Assurance: Passionate and committed  
8. Scientific Expertise: A value addition to maintain 
the scientific integrity of the products by applica-
tion of medical knowledge. 
9. Compliance Insight: Explore opportunities and re-
strictions within the environment by application of 
compliance expertise. 
Emerging markets unmet requirements: Challenges 
for pharmaceutical sector in emerging markets [7]. 
The primary challenges for pharma sector for emerging 
markets are: 
• Demographic variation 
• Diversity in culture and language 
• Differences in local government health policies and 
regulatory norms 
• Variations in medical infrastructure (healthcare facil-
ities, insurance policies) across different geograph-
ical regions  
• Scarcity of local staff with up-to-date domain 
knowledge 
• Dearth of knowledge of disease profiles of  a partic-
ular population 
Role of outsourcing industry [8]: An outsourcing indus-
try play a vital role in now-a-days effective business 
strategy for most of the pharmaceutical industry. The 
difference in the harmonization and its related com-
plexities lead to useless resourcing, operational incom-
petencies, cost escalation and delayed time-to-market. 
Outsourcing medical and scientific content develop-
ment to a proficient “functional service provider” is the 
best solution to overcome these problems. An efficient 
outsourcing partner permits pharmaceutical compa-
nies to hold the control in-house for maintaining stand-
ardization of content and creative design across globe 
catering to their local affiliates with a country. Besides, 
attending to queries from local health care provider 
(HCPs) is also provided by outsourcing industry. This 
can be done with a team of skilled resources who  can 
attain knowledge on  scientific aspects of the sponsor’s 
product portfolio by conducting comprehensive litera-
ture search, in-depth understanding of the product and 
the therapeutic area and  comparator treatments and 
then can create content pertaining to sponsor’s portfo-
lio. 
Medical writing in pharmaceutical marketing: Medical 
writing is an integral domain for the pharmaceutical 
industry. According to the CenterWatch estimates the 
medical writing market has doubled in size in the last 
five years from 2003 to 2008. Furthermore, medical 
writing has been reported as fourth most often out-
sourced service [9].  A competent medical writer 
should possess skills like correct and accurate interpre-
tation of scientific data, target audience identification,  
flawless English language skills (editing/proofreading), 
strong communication skills across different stakehold-
ers in the project (pre-clinical scientists, clinical scien-
tists, marketing department, regulatory affairs, biosta-
tistics, freelancers and consultants and senior manage-
ment)  and ability to work in pressurized conditions to 
meet deadlines. A medical writer should facilitate ra-
tional discussion between different groups to prevent 
project delays. If there is a key deadline to be kept it 
may be necessary to raise issues into the open to get a 
resolution [10-11]. 
The gamut of medical writing [11] 
Medical writing involves writing different types of doc-
uments for different target audiences ranging from 
simple newsletters to complex regulatory submissions 
(Figure 3).   
Common challenges associated with the medical 
writing :The dearth of aptitude in business and tech-
nical writing skills, high attrition rate, quality issues and 
scarcity of training programs are the main challenges 
faced by medical writers. These difficulties can be over-
come by effective management strategies adopted by 
an organization.  The primary goal of any employer 
should be to provide effective training, maintaining, 
developing and retaining its medical writers. An effec-
tive recruitment strategy highlighting proper descrip-
tion of job profile and seeking exposure to global expe-
rience, motivation and regular appraisals to keep the 
morale high and effective training programs are some 
of the prime factors for smooth functioning of a medi-
cal writing department [12, 13]. 
India as a “core” for outsourcing of medical writing 
[7,13,14] 
Int. j. clin. biomed. res. 2017;3(3): 44-49. 
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During the first few years of development of medical 
writing, Indian outsourcing companies were restricted 
by inadequate experienced staff and standardized 
training programs. However, during the last decade 
Indian companies have increased their benchmark and 
are considered as a preferred terminus for all catego-
ries of medical writing and related activities (like bio-
statistics and pharmacovigilance). The complexity, 
quality, and variety of medical writing in India have 
constantly increased. The writers now are competent 
enough to develop considerable numbers of regulato-
ry, clinical, and scientific trial related reports and post-
marketing documents both for innovator and generic 
drugs, and for all the emerged markets( US, Europe 
and Japan). Besides, Indian medical writers have also 
taken a step in associating themselves in CME, product 
labeling, pharmaceutical research analytics, and HEOR. 
The harmonization with the local populations and regu-
latory norms is important for developing both promo-
tional and non-promotional medical communications 
in emerging markets. This requires gathering of epide-
miological data for different diseases and identifying 
whether the needs of the local population differ from 
the established markets, collecting information about 
local regulatory norms and HEOR, and finding innova-
tive but cost effective ways to reach HCPs and patients. 
This is done by medical writers in India as they under-
stand the needs of non native English-speaking coun-
tries.  
Chief medical writing associations [14] 
1. The American Medical Writers Association (AMWA) 
2. The European Medical Writers Association (EMWA 
3. The All India Medical Writer's Association (AIMWA) 
4. The Drug Information Association India Medical 
Writing Community  
 
CONCLUSION 
 
An efficient MA function depends on capability of or-
ganization to hire and nurture the right expertise and 
skills.  An organization should recruit the talent with a 
vision to its wide range strategic priorities including its  
focus, structure at business unit (BU) and country level,  
formal training programs, and performance manage-
ment systems. An excel in MA requires wide range of 
skills including medical science liaisons and medical 
writers to bridge the gap between developmental 
phase of drug to its commercialization. The best way is 
to choose a strengths-based leadership strategy to 
approach for unique talents and encouraging these 
capabilities among individuals and teams. 
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